23 Sep Upperton Pharma Solutions Investment Increases Tabletting Capabilities
Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO) has significantly increased its tablet manufacturing capabilities following a strategic investment in a new state-of the-art tablet press. This investment will enhance the company’s development and manufacturing capabilities whilst strengthening their ability to support clients’ research, development and clinical manufacturing needs.
The new cutting edge tablet press, a Futorque X- by KG-Pharma is designed specifically to support both R&D studies and production batches. Indeed the unique features of this machine mean that it equally capable of producing up to 130,000 tablets per hour or supporting DoE and research studies with minimal material and can accommodate multiple tooling formats.
The tablet press is the first in a string of equipment investments being made by the CDMO as a follow-up to receiving MHRA approval for its GMP clinical manufacturing facility.
Paul Kelsall, Director of Clinical Manufacture said: ‘This is an extremely exciting time for the business as we continue to expand on our GMP processing capabilities. We are always looking to increase our capabilities, in our people, plant and processing equipment and this is a huge step forward as we look to support our clients clinical manufacturing requirements.’
Upperton Pharma Solutions develops and produces oral and inhalation drug products for clinical trials and is able to optimise formulation performance through a science-led approach to projects.
Dr Ian Lafferty, Technical Consultant added: ‘The investment in this high specification, versatile instrumented tablet machine provides Upperton Scientists with the equipment to manufacture clinical supplies and will also allow them to generate the data required to gain in-depth understanding and knowledge of process and formulation behaviour during compression that is key to supporting our clients during future scale-up, production and registration stages of their product development.’